E Fund Management Co. Ltd. Invests $143,000 in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)

E Fund Management Co. Ltd. purchased a new position in shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 11,276 shares of the company’s stock, valued at approximately $143,000.

A number of other hedge funds have also bought and sold shares of the company. First Turn Management LLC acquired a new stake in Day One Biopharmaceuticals during the third quarter valued at approximately $13,204,000. GSA Capital Partners LLP bought a new stake in shares of Day One Biopharmaceuticals in the 3rd quarter valued at approximately $825,000. Algert Global LLC raised its position in shares of Day One Biopharmaceuticals by 248.8% during the 3rd quarter. Algert Global LLC now owns 71,487 shares of the company’s stock valued at $996,000 after acquiring an additional 50,990 shares in the last quarter. SG Americas Securities LLC bought a new position in Day One Biopharmaceuticals during the fourth quarter worth $866,000. Finally, Charles Schwab Investment Management Inc. boosted its holdings in Day One Biopharmaceuticals by 14.6% in the third quarter. Charles Schwab Investment Management Inc. now owns 507,448 shares of the company’s stock worth $7,069,000 after purchasing an additional 64,700 shares during the period. 87.95% of the stock is currently owned by institutional investors and hedge funds.

Day One Biopharmaceuticals Trading Down 4.7 %

DAWN opened at $8.67 on Monday. Day One Biopharmaceuticals, Inc. has a twelve month low of $8.02 and a twelve month high of $18.07. The stock has a market cap of $878.75 million, a PE ratio of -8.42 and a beta of -1.38. The business’s 50 day moving average is $11.77 and its 200-day moving average is $13.19.

Day One Biopharmaceuticals (NASDAQ:DAWN) last announced its earnings results on Tuesday, February 25th. The company reported ($0.69) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.34). The business had revenue of $29.21 million during the quarter, compared to analysts’ expectations of $27.11 million. As a group, analysts forecast that Day One Biopharmaceuticals, Inc. will post -0.72 EPS for the current year.

Insider Activity at Day One Biopharmaceuticals

In other Day One Biopharmaceuticals news, insider Samuel C. Blackman sold 30,000 shares of the company’s stock in a transaction that occurred on Tuesday, December 10th. The stock was sold at an average price of $13.31, for a total value of $399,300.00. Following the completion of the sale, the insider now directly owns 1,034,015 shares in the company, valued at $13,762,739.65. This represents a 2.82 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Charles N. York II sold 4,370 shares of the stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $11.96, for a total value of $52,265.20. Following the transaction, the chief financial officer now directly owns 252,638 shares of the company’s stock, valued at approximately $3,021,550.48. The trade was a 1.70 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 51,064 shares of company stock worth $651,225 over the last ninety days. 8.40% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of brokerages have weighed in on DAWN. Bank of America dropped their target price on shares of Day One Biopharmaceuticals from $28.00 to $25.00 and set a “buy” rating on the stock in a report on Tuesday, January 7th. HC Wainwright dropped their price objective on shares of Day One Biopharmaceuticals from $40.00 to $36.00 and set a “buy” rating on the stock in a research note on Wednesday, February 26th. The Goldman Sachs Group decreased their target price on Day One Biopharmaceuticals from $48.00 to $43.00 and set a “buy” rating for the company in a research note on Monday, February 10th. Needham & Company LLC reiterated a “buy” rating and set a $32.00 price target on shares of Day One Biopharmaceuticals in a research report on Wednesday, February 26th. Finally, JPMorgan Chase & Co. cut their price target on Day One Biopharmaceuticals from $39.00 to $34.00 and set an “overweight” rating on the stock in a report on Wednesday, March 5th. Seven equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Day One Biopharmaceuticals has an average rating of “Buy” and a consensus target price of $34.57.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.